Radyalis In The News

LifeLine Software, Inc. to Demonstrate 3D Monte Carlo Dose Volume Quality Assurance for Photon Radiation Therapy at 2016 AAPM in Washington, D.C.

AUSTIN, Texas, July 29, 2016 /PRNewswire/ — LifeLine Software, Inc., a worldwide leader in dosimetric quality assurance tools, and Radyalis LLC, a pioneer in advanced radiotherapy software, will be demonstrating the next generation of Monte Carlo quality assurance solutions at the 2016 AAPM Annual Meeting in Washington, D.C.

This joint collaboration allows LifeLine Software to bring to market industry changing 3D dose volume independent dosimetric verification products which utilize Radyalis’ revolutionary Monte Carlo dose calculation engine for photons and electrons. Through fundamental advances in large-scale optimization and high-performance computing, LifeLine Software offerings make practical today the significant advantage of Monte Carlo accuracy for clinical usage.

In contrast to approximate analytic methods, Monte Carlo is widely recognized as the gold standard dose calculation method. Monte Carlo precisely models all relevant particle physics and materials including machine head and beam-limiting devices such as jaws, MLCs, and wedges. The most challenging clinical cases and complex structures are analyzed with the highest accuracy and confidence including heterogeneous head, neck, and lung regions, soft tissue, bony structures, and metal implants.

Flexible deployment options allow users to combine the precise accuracy of a Monte Carlo dose calculation algorithm with the levels of speed and productivity that allow busy radiation departments to meet their workflow needs. LifeLine Software offers unparalleled quality assurance accuracy and performance on current generation desktop and server platforms. A GPU is not required or necessary.

“We are excited to be demonstrating our world-class quality assurance software benefiting potentially millions of cancer patients worldwide at this year’s AAPM meeting in Washington, D.C. This effort represents our hard work and commitment to our customers to bring the best tools to market with accuracy and speed that has been unimaginable until now. Our goal is to receive FDA clearance before the end of 2016. We will immediately market RadCalc® 3DMC to all of our non-U.S. markets after beta testing and regulatory requirements are met,” said LifeLine Software’s Co-Founder and President, Jim Dube.

The flagship demonstration at AAPM is the first of two new software products both companies are collaborating on to provide more advanced modalities and capabilities for radiotherapy treatment providers. Demonstrations can be booked directly at the LifeLine Software booth #4063.

LifeLine Software’s CEO and Co-Founder Craig Laughton said, “At LifeLine Software, we have always strived to meet and exceed our customers’ expectations and to listen to their needs. With the increasing complexity of treatment delivery, the demand for sophisticated quality assurance tools has grown. This demonstration represents our hard work and commitment to our customers to bring the best 3D dose validation tools to the market. We believe the Monte Carlo dose calculation technology provided by Radyalis will not only meet our customers’ needs but exceed their expectations.”

About LifeLine Software, Inc.

Founded in 1999 by Craig Laughton (CEO) and James Dube (President), Lifeline Software Inc. is a privately held software company headquartered in Tyler, Texas servicing over 2,100 radiation oncology centers worldwide. RadCalc® was developed to provide the most comprehensive QA software program FDA 510(k) cleared to perform independent dosimetric validation calculations including 2D/3D, IMRT, Compensator IMRT, VMAT, 3D Dose Volume-Brachytherapy, Superficial, CyberKnife, Diode, and EDW support.

Press Contact LifeLine Software, Inc.

Jim Dube
LifeLine Software, Inc.
+1 866.592.1343 ext. 8
jim@lifelinesoftware.com

For more information, visit http://www.lifelinesoftware.com

About Radyalis LLC

Radyalis LLC develops and markets leadership software for radiotherapy applications that enables next-generation treatment planning and patient workflow. Based in Austin, Texas, the Radyalis team collectively brings 60+ years of related research and development experience to the particle therapy arena with focus on ultra-fast and accurate simulation and analysis methods. Radyalis has research collaborations with premier oncology research hospitals and is committed to fundamentally impacting the accuracy, productivity, and cost of treatment planning through the increased use of software automation.

Press Contact Radyalis LLC

David LaPotin
Radyalis LLC
+1 512.584.8088
David.LaPotin@radyalis.com

For more information, visit http://radyalis.com


LifeLine Software, Inc. Today Announces A New Collaboration With Radyalis LLC, An Austin, Texas Based Radiotherapy Technology Software Company

AUSTIN, Texas, Oct. 14, 2015 /PRNewswire/ — LifeLine Software, Inc., a quality assurance software company servicing radiation oncology centers worldwide, and Radyalis LLC, a leader in advanced particle therapy software, have formed a long-term collaborative relationship to allow LifeLine Software to bring to market the next-generation portfolio of industry-changing quality assurance solutions.

The flagship offering currently in development will be the first 3D Dose Volume Independent Dosimetric Verification software package that utilizes Radyalis’ revolutionary Monte Carlo dose calculation engine for photons and electrons. Radyalis’ technology has shown to be the fastest and most accurate method for Monte Carlo proton dose simulation. This unique expertise is being applied to photon and electron dose simulation with the potential of making practical today the significant advantage of Monte Carlo accuracy for clinical usage. In contrast to today’s approximate analytic methods, Monte Carlo is widely recognized as the precise gold standard dose calculation method.

Under the terms of the agreement, LifeLine Software, Inc. has worldwide rights to Radyalis’ Monte Carlo technology exclusively for secondary independent dosimetric photon and electron quality assurance applications.

Radyalis’ technology utilizes cutting-edge algorithmic and software architecture advances for unparalleled verification performance and accuracy on customers’ existing computing hardware. GPU or additional hardware acceleration is not required or necessary.

Radyalis Monte Carlo technology precisely models all relevant particle physics and physical transport including machine head and beam-limiting devices such as jaws, MLCs, and wedges. This capability allows the potential for challenging clinical cases to be analyzed with the highest accuracy and confidence such as inhomogeneous head, neck, and lung regions; critical structures; and metal implants. Intended flexible deployment options will allow users to combine the precise accuracy of a Monte Carlo dose calculation algorithm with the levels of speed and productivity that allow busy radiation departments to meet their needs.

“We are excited to be working with the Radyalis team to deliver world-class quality assurance software benefiting potentially millions of cancer patients worldwide. The goal with this collaboration is to provide both accuracy and speed that has been unimaginable until now,” said LifeLine Software’s Co-Founder and President, Jim Dube.

This agreement also provides both companies future collaborative opportunities for more advanced modalities and capabilities.

“Our goal at Radyalis is to provide leadership software technologies for radiation treatment planning and particle-therapy roadmaps. We are delighted to partner with LifeLine Software, a clear leader in the quality assurance marketplace, to bring our unique Monte Carlo technologies to the RadCalc software offering. By working with LifeLine on advanced software solutions, together we have the opportunity to fundamentally impact the radiotherapy arena and, ultimately, clinician treatment confidence,” said Radyalis’ Co-Founder and CEO, Dr. Sani Nassif.

LSI’s CEO and Co-Founder Craig Laughton said, “At LifeLine Software, we have always strived to meet and exceed our customers’ expectations and to listen to their needs.  With the increasing complexity of treatment delivery, the demand for sophisticated quality assurance tools has grown.  This partnership with Radyalis represents our commitment to our customers to bring the best 3D dose validation tools to the market.  We believe the Monte Carlo dose calculation technology provided by Radyalis will not only meet our customers’ needs but exceed their expectations.”

About LifeLine Software, Inc.

Founded in 1999 by Craig Laughton (CEO) and James Dube (President), Lifeline Software Inc. is a privately held software company headquartered in Tyler, Texas servicing over 2,000 radiation oncology centers worldwide. RadCalc® was developed to provide the most comprehensive QA software program FDA 510(k) cleared to perform independent dosimetric validation calculations including 2D/3D, IMRT, Compensator IMRT, VMAT, 3D Dose Volume-Brachytherapy, Superficial, CyberKnife, Diode, and EDW support.

Press Contact LifeLine Software, Inc.

Jim Dube
LifeLine Software, Inc.
+1 866.592.1343 ext. 8
jim@lifelinesoftware.com

For more information, visit http://www.lifelinesoftware.com

About Radyalis LLC

Radyalis LLC develops and markets high-performance software for radiotherapy applications that enables next-generation treatment planning and patient workflow. Based in Austin, Texas, the Radyalis team collectively brings 60+ years of related research and development experience to the particle therapy arena with focus on ultra-fast and accurate simulation and analysis methods. Radyalis has research collaborations with premier oncology research hospitals and is committed to fundamentally impacting the accuracy, productivity, and cost of treatment planning through the increased use of software automation.

Press Contact Radyalis LLC

David LaPotin
Radyalis LLC
David.LaPotin@radyalis.com

For more information, visit http://radyalis.com


Radyalis Collaborates With NVIDIA On Next Generation Of Monte Carlo Proton Therapy Planning Systems For Advanced Radiation Cancer Treatment

AUSTIN, Texas, July 21, 2014 /PRNewswire-iReach/ — Radyalis, a leader in advanced particle therapy software, announced today a research collaboration with NVIDIA, the world leader in visual computing, to develop unparalleled GPU-accelerated Monte Carlo dose calculation products for cancer proton therapy applications.

Proton therapy is an advanced radiation treatment method for more precisely targeting radiation dosage for treatment of inoperable cancer tumors. Monte Carlo simulation is widely recognized as the most accurate dose calculation for proton radiotherapy. To date, practical use in a clinical setting has been hindered by excessively large computational requirements.

By utilizing new advances in large-scale optimization and high-performance computing, Radyalis’ technologies make practical today the significant advantages of Monte Carlo for proton radiotherapy applications.

“The speed and accuracy of Radyalis’ high performance Monte Carlo solution will fundamentally change today’s patient treatment workflow, greatly increasing clinician’s confidence and productivity. GPU acceleration will further increase the performance which already outperforms today’s solutions,” said Dr. Evan Speight, CTO of Radyalis.

NVIDIA’s research team worked with Radyalis to accelerate the dose calculation application on NVIDIA GPU accelerators, and will continue to collaborate with Radyalis on future implementations.

“Accelerating Radyalis’ proton dose calculation performance with NVIDIA Tesla GPU technology represents an important step forward in our collaboration to enable real-time radiation cancer therapy,” said Dr. Stephen Keckler, senior director of Research, NVIDIA.

The game-changing performance of Radyalis’ dose calculator is a key enabler for next-generation treatment plan optimization, robust planning, quality assurance, and ultimately real-time adaptive planning. The speed and accuracy of Radyalis’ Monte Carlo product provides significant ROI advantages for equipment manufacturers, treatment centers, and research organizations.

ABOUT RADYALIS:

Radyalis develops and markets high performance software for radiotherapy applications that enable next-generation treatment planning and patient workflow. Based in Austin Texas, the Radyalis team collectively brings 60+ years of related research and development experience to the particle therapy arena with focus on ultra-fast and accurate scanning-beam proton applications with extensions to other particle therapy methods. Radyalis has deep collaborations with premier oncology research hospitals and is committed to fundamentally impacting the accuracy, productivity, and cost of treatment planning through the increased use of automation.

RELATED LINKS:

http://radyalis.com

Media Contact: David LaPotin, Radyalis, 512-333-1619, david.lapotin@radyalis.com


Radyalis Announces Next Generation Of Monte Carlo Proton Therapy Planning For Advanced Radiation Cancer Treatment

Fast Monte Carlo proton therapy planning made practical

AUSTIN, Texas, July 18, 2014 /PRNewswire-iReach/ — Radyalis, a leader in advanced particle therapy software, will be showcasing its high performance Monte Carlo dose calculation product for proton applications simultaneously with the 2014 American Association of Physics in Medicine (AAPM) annual meeting in Austin, TX.

Radyalis breakthroughs in large-scale optimization and high-performance computing, enables for the first time clinicians to utilize the high accuracy benefits of Monte Carlo at unprecedented speeds for proton therapy dose modeling. The Radyalis Monte Carlo engine fundamentally changes today’s radiotherapy workflow as the most complex patient treatment plans can be evaluated for efficacy and biological safety with high confidence in a matter of minutes.

Radyalis technology combines new algorithmic and software architecture advances for very high parallel efficiency on customer’s existing hardware including single and multiple node installations, clusters, and cloud platforms, for both Linux and Windows environments. Radyalis software is highly portable and very flexible, and designed to be integrated via a customer API or into a treatment planner.

Without compromise, Radyalis Monte Carlo supports a robust set of features. All relevant physics are accurately modeled. Simulation of complex geometries, NIST materials, and multiple beams are fully supported. Radyalis provides sophisticated dosage statistics including particle distributions, variability, fluence, and linear energy transfer, further guiding the radiation physicist.

The Radyalis fast and accurate Monte Carlo dose calculator is a key enabler for next-generation treatment plan optimization, robust planning, quality assurance, and ultimately real-time adaptive planning. The speed and accuracy of Radyalis’ Monte Carlo product provides significant ROI advantages for equipment manufacturers, treatment centers, and research organizations.

ABOUT RADYALIS

Radyalis develops and markets high performance software for radiotherapy applications that enable next-generation treatment planning and patient workflow. Based in Austin, Texas, the Radyalis team collectively brings 60+ years of related research and development experience to the particle therapy arena with focus on ultra-fast and accurate scanning-beam proton applications with extensions to other particle therapy methods. Radyalis has deep collaborations with premier oncology research hospitals and is committed to fundamentally impacting the accuracy, productivity, and cost of treatment planning through the increased use of automation.

RELATED LINKS

http://radyalis.com

Media Contact: David LaPotin, Radyalis, 512-333-1619, david.lapotin@radyalis.com